The FDA actively – and unusually – collaborated with a biopharmaceutical company to pursue the approval of an Alzheimer's Disease drug, despite many questions about its efficacy and astronomical price. A congressional investigation found that the FDA’s approval process was “rife with irregularities" and that the agency’s actions “raise serious concerns about FDA’s lapses in protocol.”
